...
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history
【24h】

Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history

机译:在44年内,原发性胆管炎患者的升级疾病阶段:一种不断变化的自然历史

获取原文
获取原文并翻译 | 示例
           

摘要

Changes over time in the presenting features and clinical course of patients with primary biliary cholangitis are poorly described. We sought to describe temporal trends in patient and disease characteristics over a 44‐year period across a large international primary biliary cholangitis cohort of 4,805 patients diagnosed between 1970 and 2014, from 17 centers across Europe and North America. Patients were divided into five cohorts according to their year of diagnosis: 1970‐1979 (n = 143), 1980‐1989 (n = 858), 1990‐1999 (n = 1,754), 2000‐2009 (n = 1,815), and ≥2010 (n = 235). Age at diagnosis, disease stage, response to ursodeoxycholic acid, and clinical outcomes were compared. Mean age at diagnosis increased incrementally by 2‐3 years per decade from 46.9 ± 10.1 years in the 1970s to 57.0 ± 12.1 years from 2010 onward ( P 0.001). The female to male ratio (9:1) and antimitochondrial antibody positivity (90%) were not significantly variable. The proportion of patients presenting with mild biochemical disease (according to Rotterdam staging) increased from 41.3% in the 1970s to 72.2% in the 1990s ( P 0.001) and remained relatively stable thereafter. Patients with a mild histological stage at diagnosis increased from 60.4% (1970‐1989) to 76.5% (1990‐2014) ( P 0.001). Correspondingly, response to ursodeoxycholic acid according to Paris‐I criteria increased; 51.7% in the 1970s and 70.5% in the 1990s ( P 0.001). Recent decades were also characterized by lower decompensation rates (18.5% in the 1970s to 5.8% in the 2000s, P 0.001) and higher 10‐year transplant‐free survival (48.4%, 68.7%, 79.7%, and 80.1% for each respective cohort; P 0.001). Conclusion: In recent decades, a pattern of primary biliary cholangitis presentation consistent with an older age at diagnosis alongside reduced disease severity has been noted; the observed trends may be explained by an increase in routine testing of liver function and/or a changing environmental trigger. (H epatology 2018;67:1920‐1930).
机译:患有原发性胆管炎患者的呈现特征和临床过程中的随时间变化很差。我们试图描述在1970年至2014年间诊断的4,805名患者的4,805名患者,从欧洲和北美诊断的大型国际胆管炎群组中的4,805名患者的患者和疾病特征中的时间趋势。根据诊断年份分为五个队列:1970-1979(n = 143),1980-1989(n = 858),1990-1999(n = 1,754),2000-2009(n = 1,815),和≥2010(n = 235)。在诊断中,疾病阶段,对核致氧酸的反应以及临床结果进行了疾病。诊断的平均年龄在20世纪70年代在20世纪70年代的46.9±10.1岁以上逐步增加2-3岁至2010年的57.0±12.1岁(P <0.001)。女性对阳性比(9:1)和抗度粒细胞抗体阳性(90%)不显着变化。患有轻度生化疾病(根据鹿特丹分期)的患者比例从20世纪70年代的41.3%增加到20世纪90年代(P <0.001)的72.2%,此后保持相对稳定。在诊断中轻度组织学阶段的患者从60.4%(1970-1989)增加到76.5%(1990-2014)(P <0.001)。相应地,根据巴黎-i标准对核致氧胆酸的反应增加; 20世纪70年代51.7%和20世纪90年代的70.5%(P <0.001)。近几十年的特点也具有较低的失代偿率(20世纪70年代的18.5%,在2000年代的5.8%,P <0.001)和较高的10年移植生存率(48.4%,68.7%,79.7%和80.1%每个相应的队列; p <0.001)。结论:近几十年来,已经注意到患有较老年龄较大的疾病严重程度的年龄一致的原发性胆管炎呈现模式;观察到的趋势可以通过肝功能和/或改变环境触发的常规测试的增加来解释。 (2018年Hopatology; 67:1920-1930)。

著录项

  • 来源
  • 作者单位

    Toronto Centre for Liver Disease Toronto General HospitalUniversity Health NetworkToronto ON Canada;

    Gastroenterology and HepatologyErasmus University Medical CenterRotterdam The Netherlands;

    Gastroenterology and HepatologyErasmus University Medical CenterRotterdam The Netherlands;

    Toronto Centre for Liver Disease Toronto General HospitalUniversity Health NetworkToronto ON Canada;

    Gastroenterology and HepatologyErasmus University Medical CenterRotterdam The Netherlands;

    Department of Gastroenterology and HepatologyAcademic Medical CenterAmsterdam The Netherlands;

    Division of Gastroenterology and Center for Autoimmune Liver Diseases Department of Medicine and;

    Divison of Gastroenterology and HepatologyUniversity of AlbertaEdmonton AB Canada;

    Centre de Référence des Maladies Inflammatoires des VoiesBiliairesH?pital Saint‐AntoineParis France;

    Division of Gastroenterology and Center for Autoimmune Liver Diseases Department of Medicine and;

    Digestive and Liver diseasesUT Southwestern Medical CenterDallas TX;

    Department of Health SciencesUniversità degli Studi di MilanoMilan Italy;

    Department of Surgery Oncology and GastroenterologyUniversity of PaduaPadua Italy;

    Liver Unit Hospital Clínic CIBERehd IDIBAPSUniversity of BarcelonaBarcelona Spain;

    Department of HepatologyUniversity Hospitals Leuven KU LeuvenLeuven Belgium;

    Liver Care NetworkSwedish Medical CenterSeattle WA;

    Department of Internal Medicine IV Jena University HospitalFriedrich Schiller University of;

    Department of Medicine and Research Laboratory of Internal MedicineUniversity of ThessalyLarissa;

    The Sheila Sherlock Liver CentreThe Royal Free HospitalLondon UK;

    NIHR Biomedical Research Centre and Centre for Liver ResearchUniversity of BirminghamBirmingham UK;

    Division of Gastroenterology and HepatologyMayo ClinicRochester MN;

    Arizona State UniversityPhoenix AZ;

    Department of Medicine and Research Laboratory of Internal MedicineUniversity of ThessalyLarissa;

    Centre de Référence des Maladies Inflammatoires des VoiesBiliairesH?pital Saint‐AntoineParis France;

    NIHR Biomedical Research Centre and Centre for Liver ResearchUniversity of BirminghamBirmingham UK;

    Department of Gastroenterology and HepatologyGhent University HospitalGhent Belgium;

    Toronto Centre for Liver Disease Toronto General HospitalUniversity Health NetworkToronto ON Canada;

    Toronto Centre for Liver Disease Toronto General HospitalUniversity Health NetworkToronto ON Canada;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 消化系及腹部疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号